 |
8 Diseases |  |
17 Trials |
|
17 Trials |  |
2602 News |  |
| «12345678910111213...2425» |
- | Lemtrada (alemtuzumab) / Sanofi
Observational data, Journal: Comment on "Alemtuzumab improves cognitive processing speed in active multiple sclerosis - a longitudinal observational study". (Pubmed Central) - Dec 1, 2022
No abstract available
- | Lemtrada (alemtuzumab) / Sanofi
Journal, HEOR: Health economic outcomes of switching to alemtuzumab from other disease-modifying therapies in people with multiple sclerosis in the USA. (Pubmed Central) - Nov 29, 2022
DMT costs reduced over the same period. Health economic and clinical benefits were seen following switching to alemtuzumab from other DMTs for treatment of MS, in this cohort from the USA.
- | Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Retrospective data, Journal: The independent contribution of brain, spinal cord and gadolinium MRI in treatment decision in multiple sclerosis: A population-based retrospective study. (Pubmed Central) - Nov 28, 2022
Health economic and clinical benefits were seen following switching to alemtuzumab from other DMTs for treatment of MS, in this cohort from the USA. Our results show that spinal cord and Gd MRI acquisitions can provide relevant information to influence subsequent treatment decisions, especially in early treatment phases, compared with stand-alone brain MRI.
- || Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Retrospective data, Review, Journal: Systematic review and network meta-analysis (NMA) for cladribine tablets in achieving sustained disability improvement (SDI) in multiple sclerosis. (Pubmed Central) - Nov 25, 2022
Of all considered therapies, treatment with cladribine tablets was associated with a higher probability of sustained disability improvement in RRMS patients. As this conclusion is based on available clinical data of limited quality, future studies, as well as real-world data, would be valuable to provide further evidence regarding the comparative effectiveness of RRMS therapies.
- | Lemtrada (alemtuzumab) / Sanofi
Journal, Real-world evidence: Satisfaction with alemtuzumab in relapsing multiple sclerosis patients: Results from the real-world PRO-ACT study. (Pubmed Central) - Nov 22, 2022
Most (95.0%) patients experienced ≥ 1 AE (88.4% mild, 67.8% moderate). The primary endpoint was met; the safety of alemtuzumab was consistent with pivotal studies.
- Tysabri (natalizumab) / Biogen, Royalty, Lemtrada (alemtuzumab) / Sanofi
Alemtuzumab following natalizumab in pediatric- and adult-onset multiple sclerosis () - Nov 20, 2022 - Abstract #AECF2022AECF_7;
ALZ seems more effective in AOMS than in POMS following NTZ. Additional studies are needed to clarify whether ALZ (or more broadly, induction therapies) might be an effective therapeutic approach for POMS, especially when shifting from NTZ, and if an addition ALZ course should be always considered in younger patients, especially in POMS.
- | Lemtrada (alemtuzumab) / Sanofi
Journal, IO biomarker: Trans-Endothelial Migration of Memory T Cells Is Impaired in Alemtuzumab-Treated Multiple Sclerosis Patients. (Pubmed Central) - Nov 16, 2022
CD62L expression was lower on CD4 T cells than CD4 T cells and decreased further in alemtuzumab-treated patients. These data suggest that repopulated memory T cells are phenotypically different from naïve T cells, which may affect their transmigration across the BBB in vitro.
- | Lemtrada (alemtuzumab) / Sanofi
Journal: Severe Autoimmune intravascular hemolytic anemia in patients receiving Alemtuzumab for Multiple sclerosis. (Pubmed Central) - Nov 15, 2022
These data suggest that repopulated memory T cells are phenotypically different from naïve T cells, which may affect their transmigration across the BBB in vitro. No abstract available
- | Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Journal, HEOR: Economic evaluation of cladribine tablets in high disease activity (HDA) relapsing multiple sclerosis (RMS) patients in Lebanon. (Pubmed Central) - Nov 10, 2022
No abstract available Cladribine tablets are a cost-effective and a budget-saving treatment option for the treatment of HDA-RMS patients in Lebanon from the NSSF perspective.
- || Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Review, Journal: High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing-Remitting Multiple Sclerosis. (Pubmed Central) - Nov 10, 2022
In this review, we provide an overview of the DMT options and MS treatment strategies, and discuss the clinical benefits of HETs (including ofatumumab, ocrelizumab, natalizumab, alemtuzumab, and cladribine) in the early stages of MS, along with safety concerns associated with these DMTs. By minimizing the accumulation of neurological damage early in the disease course, early treatment with HETs may enhance long-term clinical outcomes over the lifetime of the patient.
- Lemtrada (alemtuzumab) / Sanofi
Distinct Patterns in the Reconstitutions of Treg and T-Helper Subsets after Autologous Hematopoietic Stem Cell Transplantation in Juvenile-Onset Systemic Sclerosis Patients (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_4816;
Acknowledgements: We thank all participating patients, nurses, physicians, and scientists in this study for their contributions. The study was supported by the “Idea Development Award” from the Department of Defense – Scleroderma Research Program (Award number W81XWH-21-1-0782 and W81XWH-21-1-0783).
- | Lemtrada (alemtuzumab) / Sanofi
Biomarker, Journal: Ella versus Simoa Serum Neurofilament Assessment to Monitor Treatment Response in Highly Active Multiple Sclerosis Patients. (Pubmed Central) - Oct 28, 2022
In order to assess the methods agreement, Bland-Altman plots and Passing-Bablok regression were analyzed. Here, we show that despite the fact that Ella measures around 24% higher values than Simoa, both are equally suitable for longitudinal sNfL monitoring.
- Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
ALEMTUZUMAB‐INDUCED AUTOIMMUNE THYROID DISEASE‐ CLINICAL AND BIOCHEMICAL COURSE () - Oct 26, 2022 - Abstract #ATA2022ATA_460;
Thirty‐nine (39%) developed autoimmune thyroid disease, of whom 35 patients (30%) had GD. Median time from first dose of alemtuzumab to diagnosis of thyroid disease was 25 (range 12‐64) months.
- | Lemtrada (alemtuzumab) / Sanofi
Observational data, Journal: Acute infusion effects in relapsing multiple sclerosis patients receiving alemtuzumab under a modified prophylaxis regimen. (Pubmed Central) - Oct 20, 2022
P
Median time from first dose of alemtuzumab to diagnosis of thyroid disease was 25 (range 12‐64) months. The modified peri-infusion prophylaxis regimen was well tolerated and may reduce incidence of acute SBP increase.
- Lemtrada (alemtuzumab) / Sanofi
COVID-19 immunity in Multiple Sclerosis: Living with MS on DMTs a year after COVID-19 vaccination (ePoster Area) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_2057;
Aims and Objectives: To evaluate if people with MS on and off disease modification treatments) (DMT) develop and maintain adequate adaptive immune response after the completed course of Covid-19 vaccination compared to healthy controls (HC) We recruited people with MS on and off DMT (n=210; Ocrelizumab, Alemtuzumab, Natalizumab, Fingolimod, Tecfidera, Interferon, no-DMT n=30 each) and HC (n=30) a year since 1st covid-19 vaccine. This study presents novel data informing care of People with MS and vaccination policies.
- Socioeconomic Influence on DMT Prescribing Strategies (ePoster Area) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_2000;
This difference was seen early in the study with all levels of socioeconomic status trending toward similar rates of high efficacy prescribing by the end. The cause for this lower rate of high-efficacy prescribing will require further evaluation; one theory is that patient assistance programs may distort the economics of DMT affordability for this quartile of patients.
- Lemtrada (alemtuzumab) / Sanofi
Early use of high efficacy therapies in pediatric forms of relapsing-remitting multiple sclerosis: a real-life observational study (ePoster Theatre 4) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_1991;
Rapid initiation of more aggressive treatment may allow better disease control. However, the effect on EDSS worsening remains uncertain, probably due to the small number of events and the short follow-up duration.
- Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Horizontal versus vertical switch of treatment in patients with relapsing-remitting multiple sclerosis in Austria (ePoster Theatre 4) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_1847;
A horizontal switch after a platform therapy revealed a higher relapse probability and a trend towards less EDDS improvements comparing to a vertical switch in Austrian RRMS patients. Therefore, switching to a higher efficacy treatment should be preferred in the case of treatment failure.
- DMT Persistence: we've started, when will we stop? (ePoster Area) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_1766;
This multi-centre study has revealed highly variable persistence between DMTs over time, which may impact real-world effectiveness. These results may inform DMT clinical decision-making and improve outcomes for pwMS.
- Lemtrada (alemtuzumab) / Sanofi
Early use of high efficacy therapies in pediatric forms of relapsing-remitting multiple sclerosis: a real-life observational study (ePoster Area) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_1744;
Rapid initiation of more aggressive treatment may allow better disease control. However, the effect on EDSS worsening remains uncertain, probably due to the small number of events and the short follow-up duration.
- Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Barriers to Access Multiple Sclerosis Disease-Modifying Therapies in Middle East and North Africa: A Regional Survey-Based Study (ePoster Area) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_1718;
Most MENA countries have access to DMTs, including high-efficacy DMTs. However, more than half of them report problems with treatment continuation with cost being the major barrier to treatment.
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Spike antibody seroconversion and breadth following SARS-CoV-2 vaccination in Australian people with Multiple Sclerosis (ePoster Area) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_1627;
Some DMTs reduce Spike antibody titres or prevent seroconversion. The sequence of Spike used in the first generation of vaccines may need to be updated for emerging VoC.
- Lemtrada (alemtuzumab) / Sanofi
COVID-19 Severity and Vaccination Effect in Persons with MS Treated with Alemtuzumab (ePoster Area) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_1594;
There is no evidence of any increased risk for severe COVID-19 in pwMS treated with alemtuzumab. In these patients, humoral response to anti-SARS-CoV-2 vaccine was high and comparable to those treated with other DMTs or untreated.
- Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Humoral immune response to SARS-CoV-2 booster vaccination in patients with multiple sclerosis and healthy controls: a prospective multicenter study (ePoster Area) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_1574;
Humoral response to SARS-CoV-2 booster vaccination in pwMS is excellent. While reduced by S1PMs and CD20mAb, protective response is still expected in the majority of patients.
- Lemtrada (alemtuzumab) / Sanofi
Clinical characteristics and disability progression in late-onset MS (ePoster Area) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_1404;
Around half of the treated LOMS (54.5%) had been exposed to high efficacy therapies (fingolimod, natalizumab, rituximab, ocrelizumab, alemtuzumab, daclizumab and HSCT) compared to almost two thirds of AOMS (66.1 %). Significant differences in clinical characteristics, treatment approaches and risk for disability progression distinguish LOMS from AOMS.
- Lemtrada (alemtuzumab) / Sanofi
Transcriptome alterations in peripheral blood B cells of patients with multiple sclerosis under immune reconstitution therapy (ePoster Area) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_1314;
We show that B cells circulating in the blood of patients with MS under IRT present a distinct gene expression signature, and we delineated the associated biological processes and gene interactions. Moreover, we identified candidate genes whose expression may be an indicator of relapse risk, but further studies are needed to substantiate their potential predictive value.
- Lemtrada (alemtuzumab) / Sanofi
Existing claims-based algorithm may overestimate relapses in multiple sclerosis (MS) patients using infusible disease modifying therapies (DMTs) that require steroid premedication (ePoster Area) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_1298;
This is contrary to clinical trial and practice, suggesting continued overestimation of relapses in IV mAbs due to unmeasured confounding. This algorithm warrants further revision to accurately estimate relapses in the age of mAbs.
- Tysabri (natalizumab) / Biogen, Royalty, Lemtrada (alemtuzumab) / Sanofi
Shifting from Natalizumab to Alemtuzumab in Pediatric-Onset Multiple Sclerosis (ePoster Area) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_1116;
In POMS shifting from natalizumab, alemtuzumab is an effective option. The moderate NEDA condition needs to be further evaluated compared with pediatric cohorts not treated with alemtuzumab and with alemtuzumab-treated adult-onset MS.
- Lemtrada (alemtuzumab) / Sanofi
Effective humoral and cellular immunity in mRNA-COVID-19 multiple sclerosis vaccinees treated with alemtuzumab (ePoster Area) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_1062;
P=N/A
We prospectively measured (1) SARS-COV-2 IgG response using a quantitative anti-spike protein-based immunoassay (Euroimmun, Lubeck, Germany, cut-off IgG level >35.2 BAU/ml), (2) memory B-cells specific for SARS-CoV-2 RBD, and (3) memory T-cells secreting IFN-g and/or IL-2, in response to SARS-CoV-2 peptides by ELISpot/Fluorospot assays, in MS patients vaccinated with BNT162b2-COVID-19 vaccine before, one and three months after the second vaccine dose. Alemtuzumab treatment enabled effective humoral and cellular immune responses at 1 month and 3 months following COVID-19 vaccination.
- Mavenclad (cladribine) / EMD Serono
Real-world experience switching from high-efficacy infusions to cladribine tablets (ePoster Area) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_1000;
There were no new safety signals. ARR was decreased.
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
A changing target - adapting ongoing autologous haematopoietic stem cell transplantation clinical trials to evolving clinical practice in the treatment of highly active relapsing remitting multiple sclerosis (ePoster Area) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_988;
aHSCT is delivered using non-myeloablative conditioning with a cyclophosphamide/anti-thymocyte globulin regimen followed by an unselected autologous graft... Clinical trials must be responsive to changing clinical practice to ensure success and relevance to the target patient population.
- Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Evaluation of the use of High Efficacy Treatments (HETs) in patients with relapsing remitting multiple sclerosis in Argentina (ePoster Area) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_967;
Patients diagnosed with Relapsing Remitting MS (RRMS) according to validated diagnosis criteria and under HETs (natalizumab, alemtuzumab, cladribine, rituximab or ocrelizumab) were included. Our study showed a significant trend towards and a rapid increase in the use of HET in clinical practice.
- Lemtrada (alemtuzumab) / Sanofi
A long term multicenter observational study on the efficacy and safety of alemtuzumab in multiple sclerosis highly active naïve patients (ePoster Area) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_965;
These results strengthen the assumption that aggressive naïve patient is an ideal candidate for immune system resetting, likely due to young age, short disease duration and low disability. Furthermore, absence of previous immunomodulating/immunosuppressant drugs altering the immune system could play a key role in determining effectiveness of this powerful drug.
- Lemtrada (alemtuzumab) / Sanofi
Comparative effectiveness of autologous haematopoietic stem cell transplantation with immune reconstitution therapies in relapsing-remitting MS (ePoster Area) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_960;
There was evidence for superior prevention of relapses by AHSCT than by mitoxantrone, but no evidence for difference in disability outcomes. Further comparison of AHSCT to these therapies in cohorts and trials over extended time is warranted.
- Lemtrada (alemtuzumab) / Sanofi
Autologous hematopoietic stem cell transplantation in multiple sclerosis: updating outcomes in the Valencian cohort (ePoster Area) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_955;
aHSCT as an alternative therapy to manage aggressive MS patients is a relatively safe and effective procedure. It is necessary to propose comparative studies with adverse effects and effectiveness between immunomodulatory treatments and aHSCT.
- Lemtrada (alemtuzumab) / Sanofi
Tumefactive demyelinating lesions in multiple sclerosis 24 months after the 2nd cycle of alemtuzumab: changes in immune cell populations and candidate biomarkers (ePoster Area) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_946;
TDLs can appear after 24 months of the 2nd cycle of alemtuzumab in MS. These results suggest that the increase of Th1/Th17 cells could be a candidate biomarker of TDLs in MS patients treated with alemtuzumab.
- Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Achieving No Evidence of Disease Activity-3 (NEDA-3) in cladribine and monoclonal antibodies treated multiple sclerosis patients (ePoster Area) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_859;
We found a high proportion of patients who achieved NEDA-3 at 1 and 2 years. Treatment- naïve patients had a higher risk of achieving NEDA-3 at 2 years
- Mavenclad (cladribine) / EMD Serono
Treatment emergent adverse events experienced early and transiently in the treatment course with cladribine tablets: data from the CLEVER real-world study (ePoster Area) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_844;
Following this 45-day time period the rest of the AEs were distributed over the remaining observation time with proportionally less AEs and affected patients. This is in line with the post hoc analysis of CLARITY and ORACLE-MS safety.
- Lemtrada (alemtuzumab) / Sanofi
Proof of Concept for 2-stage Models of Heterogeneous Treatment Effects Derived from the Real-World MS PATHS Research Network (ePoster Area) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_841;
DMT groups were based on efficacy: high (natalizumab, ocrelizumab, alemtuzumab, ofatumumab, rituximab), moderate (fumarates, S1PR modulators, and cladribine) and low (teriflunomide, interferons, glatiramer acetate)... 2-stage models of HTE in MS PATHS replicated CT findings providing proof of concept for expanding this methodology into RWD.
- Lemtrada (alemtuzumab) / Sanofi
Drivers of therapy switch in Relapsing Multiple Sclerosis: a study from the Italian MS Registry (ePoster Area) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_829;
Clinical disease activity is an important trigger of treatment switch in RMS patients. HE DMTs, especially those with anti-CD20 MoA, significantly reduce the risk of disease activity in RMS.
- Lemtrada (alemtuzumab) / Sanofi
Assessment of persistence to Disease Modifying Treatments in patients with Multiple Sclerosis (ePoster Area) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_826;
In NP we found a trend for a longer PER with DMF and GA. In PPrev, ALZ showed a longer PER, followed by DMF.
- Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Horizontal versus vertical switch of treatment in patients with relapsing-remitting multiple sclerosis in Austria (ePoster Area) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_825;
A horizontal switch after a platform therapy revealed a higher relapse probability and a trend towards less EDDS improvements comparing to a vertical switch in Austrian RRMS patients. Therefore, switching to a higher efficacy treatment should be preferred in the case of treatment failure.
- Lemtrada (alemtuzumab) / Sanofi
The effect of alemtuzumab treatment on neurodegeneration in relapsing remitting multiple sclerosis: real-world data from a five-year prospective one center study (ePoster Area) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_817;
In this prospective observational study of ALZ treated patients, measures of degeneration were essentially unchanged or improved after 5 years of follow-up. However, OCT revealed further degeneration of RNFL in patients with clinical or MRI signs of disease activity.
- Lemtrada (alemtuzumab) / Sanofi
Neurodegeneration quantitative systems pharmacology modelling for analysis of multiple sclerosis therapy (ePoster Area) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_810;
Citations: [1] Martin, S-J et al. J neurol, neurosurg, and psychiatry vol.
- Lemtrada (alemtuzumab) / Sanofi
The brain-age paradigm and clinical outcomes in multiple sclerosis (ePoster Area) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_682;
Results indicate that MS patients exhibit accelerated brain aging; greater brain-PAD was observed among those diagnosed atyounger age and with higher EDSS. More severe longitudinal changes in brain-PAD are observed in the early stage of the disease, among patients with a shorter disease duration, and could be used as biomarker to monitor treatment response.
- Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Trends in the use of disease-modifying therapies in pre-pregnant, pregnant, and postpartum women with multiple sclerosis in the United States: 2016-2021 (ePoster Area) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_602;
DMT use duration may not account for pre-pregnancy extended dosing, potentially underestimating DMT use. Further data are needed to better understand potential paradigm shifts in DMT use in women of childbearing age.
- | Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
Journal: Consensus statement on the use of alemtuzumab in daily clinical practice in Spain. (Pubmed Central) - Oct 11, 2022
Further data are needed to better understand potential paradigm shifts in DMT use in women of childbearing age. The present document is intended to be used as a tool for optimising the management of alemtuzumab in routine clinical practice.
- | Lemtrada (alemtuzumab) / Sanofi
Journal: Author response to comment on: Alopecia in multiple sclerosis patients treated with disease modifying therapies. (Pubmed Central) - Oct 7, 2022
The present document is intended to be used as a tool for optimising the management of alemtuzumab in routine clinical practice. No abstract available
- | Mavenclad (cladribine) / EMD Serono, Ocrevus (ocrelizumab) / Roche, Lemtrada (alemtuzumab) / Sanofi
Trial completion date, Trial primary completion date: Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS) (clinicaltrials.gov) - Oct 7, 2022
P3, N=100, Recruiting, Sponsor: Haukeland University Hospital
No abstract available Trial completion date: Mar 2025 --> Mar 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
- || Lemtrada (alemtuzumab) / Sanofi
Review, Journal: Antibody-mediated cell depletion therapies in multiple sclerosis. (Pubmed Central) - Oct 6, 2022
Ab-mediated immune cell depletion therapies include the CD52-targeting mAb alemtuzumab, CD20-specific therapeutics, and new Ab-based treatments which are currently being developed and tested in clinical trials. Here, we review recent developments in effector mechanisms and clinical applications of Ab-based cell depletion therapies, compare their immunological and clinical effects with the prototypic immune reconstitution treatment strategy, autologous hematopoietic stem cell transplantation, and discuss their potential to restore immunological tolerance and to achieve durable remission in people with MS.